Cargando…
Protein Kinases and Parkinson’s Disease
Currently, the lack of new drug candidates for the treatment of major neurological disorders such as Parkinson’s disease has intensified the search for drugs that can be repurposed or repositioned for such treatment. Typically, the search focuses on drugs that have been approved and are used clinica...
Autores principales: | Mehdi, Syed Jafar, Rosas-Hernandez, Hector, Cuevas, Elvis, Lantz, Susan M., Barger, Steven W., Sarkar, Sumit, Paule, Merle G., Ali, Syed F., Imam, Syed Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037850/ https://www.ncbi.nlm.nih.gov/pubmed/27657053 http://dx.doi.org/10.3390/ijms17091585 |
Ejemplares similares
-
Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives
por: Sarkar, Sumit, et al.
Publicado: (2016) -
Autophagy and protein aggregation as a mechanism of dopaminergic degeneration in a primary human dopaminergic neuronal model
por: Cuevas, Elvis, et al.
Publicado: (2022) -
Neuroprotective Efficacy of a New Brain-Penetrating C-Abl Inhibitor in a Murine Parkinson’s Disease Model
por: Imam, Syed Z., et al.
Publicado: (2013) -
Ketamine-Induced Neurotoxicity and Changes in Gene Expression in the Developing Rat Brain
por: Liu, Fang, et al.
Publicado: (2011) -
Molecular Aspects of Dopaminergic Neurodegeneration: Gene-Environment Interaction in Parkin Dysfunction
por: Ali, Syed F., et al.
Publicado: (2011)